<DOC>
	<DOCNO>NCT00476424</DOCNO>
	<brief_summary>A Pharmacokinetic study daily Efavirenz 400 mg versus 600 mg Thai HIV-1 infected subject .</brief_summary>
	<brief_title>A Pharmacokinetic Study Once Daily Efavirenz 400 mg Versus 600 mg Thai HIV-1 Infected Subjects</brief_title>
	<detailed_description>Efavirenz Pharmacokinetic evaluation support once-daily dosing ( T1/2 10-52 hour ) . The recommended dosage efavirenz combination nucleoside reverse transcriptase inhibitor ( NRTI ) and/or protease inhibitor ( PI ) 600mg orally , daily . In Thai population , many ARV level high . We believe 600 mg efavirenz high Thai people would like see pharmacokinetic data safety efficacy efavirenz 400 mg .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Age &gt; 18 year age old HIV1 infection Who stable PIbased highly active antiretroviral therapy HIV1 RNA &lt; 50 copies/ml within 6 month . No active opportunistic infection . Sexually active subject must willing use effective form birth control . Able provide write informed consent . Pregnant breastfeeding female exclude . Inability understand nature extent study procedure require . ALT/ AST 5x upper limit Relevant history current condition , illness might interfere drug absorption , distribution , metabolism excretion . Use concomitant medication may interfere pharmacokinetics efavienz History sensitivity/idiosyncrasy drug chemically related compound may employ study . Active drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>daily Efavirenz 400 mg</keyword>
	<keyword>PK daily Efavirenz 400 mg versus 600 mg</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>